Martin Henry Poleski

Professor of Medicine
Campus mail 0351D Duke South Bldg, Orange Zone, Durham, NC 27710
Phone (919) 684-1817
In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Memorial Sloan Kettering Cancer Center, 1976 - 1978
  • Medical Resident, Medicine, Jewish Hospital (Canada), 1974 - 1976
  • M.D.C.M., McGill University (Canada), 1973

Publications

Cardona, Diana M., Claire J. Detweiler, Michael J. Shealy, Anthony D. Sung, Daniel M. Wild, Martin H. Poleski, Bryan L. Balmadrid, Constance T. Cirrincione, David N. Howell, and Keith M. Sullivan. “Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease..” Arch Pathol Lab Med 142, no. 9 (September 2018): 1098–1105. https://doi.org/10.5858/arpa.2017-0054-OA.

PMID
29697275
Full Text

Sung, Anthony D., Syed Hassan, Diana M. Cardona, Daniel Wild, Krista Rowe Nichols, Hossein Mehdikhani, Bryan Balmadrid, et al. “Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults..” Biol Blood Marrow Transplant 24, no. 4 (April 2018): 734–40. https://doi.org/10.1016/j.bbmt.2017.12.772.

PMID
29246821
Full Text

Wild, Daniel, Anthony D. Sung, Diana Cardona, Constance Cirricione, Keith Sullivan, Claire Detweiler, Michael Shealy, et al. “The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review..” Dig Dis Sci 61, no. 3 (March 2016): 806–13. https://doi.org/10.1007/s10620-015-3938-8.

PMID
26537485
Full Text

Coutré, Steven E., Jacqueline C. Barrientos, Jennifer R. Brown, Sven de Vos, Richard R. Furman, Michael J. Keating, Daniel Li, et al. “Management of adverse events associated with idelalisib treatment: expert panel opinion..” Leuk Lymphoma 56, no. 10 (2015): 2779–86. https://doi.org/10.3109/10428194.2015.1022770.

PMID
25726955
Full Text

Shah, Tilak Upendra, Rodger Liddle, M Stanley Branch, Paul Jowell, Jorge Obando, and Martin Poleski. “Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial..” Jop 13, no. 5 (September 10, 2012): 514–18. https://doi.org/10.6092/1590-8577/855.

PMID
22964958
Full Text

Willett, Christopher G., Dan G. Duda, Marek Ancukiewicz, Mira Shah, Brian G. Czito, Rex Bentley, Martin Poleski, et al. “A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer..” Oncologist 15, no. 8 (2010): 845–51. https://doi.org/10.1634/theoncologist.2010-0030.

PMID
20667969
Full Text

Duda, Dan G., Christopher G. Willett, Marek Ancukiewicz, Emmanuelle di Tomaso, Mira Shah, Brian G. Czito, Rex Bentley, et al. “Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer..” Oncologist 15, no. 6 (2010): 577–83. https://doi.org/10.1634/theoncologist.2010-0029.

PMID
20484123
Full Text

Xu, Lei, Dan G. Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Daniel C. Chung, Gregory Y. Lauwers, Rekha Samuel, et al. “Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer..” Cancer Res 69, no. 20 (October 15, 2009): 7905–10. https://doi.org/10.1158/0008-5472.CAN-09-2099.

PMID
19826039
Full Text

Willett, Christopher G., Dan G. Duda, Emmanuelle di Tomaso, Yves Boucher, Marek Ancukiewicz, Dushyant V. Sahani, Johanna Lahdenranta, et al. “Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study..” J Clin Oncol 27, no. 18 (June 20, 2009): 3020–26. https://doi.org/10.1200/JCO.2008.21.1771.

PMID
19470921
Full Text

Pages